drugset
drugset / Trial / NCT04713761

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

NCT04713761 ↗

Phase 2 Unknown 15 enrolled Shanghai Pulmonary Hospital, Shanghai, China
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced malignant MPM.

Timeline

Start
2021-02-01
Primary completion
2022-01-31
Completion
2025-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

malignant pleural mesothelioma